JMP Securities Downgrades Carbylan Therapeutics (CBYL) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Carbylan Therapeutics (CBYL) Announces Suspension of Further Hydros-TA Development; Exploring Strategic Transaction
April 15, 2016 7:31 AM EDTCarbylan Therapeutics (Nasdaq: CBYL) announced that it has suspended further clinical development of Hydros-TA and that it is actively pursuing a strategic transaction, including a merger or acquisition of the company. As previously announced, Carbylan has engaged Wedbush PacGrow to act as its... More
Carbylan Therapeutics (CBYL) trading halted with news pending
April 15, 2016 7:30 AM EDTCarbylan Therapeutics (NASDAQ: CBYL) trading halted with news pending.
... More